

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Walsh et al.	Group No.:	1645
Serial No.:	10/733,046	Examiner:	V. L. Ford
Filed:	December 10, 2003		
Entitled:	TOPICAL ANTI-INFECTIVE FORMULATIONS		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT LETTER

EFS WEB FILED  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir or Madam:

The citations listed in the attached IDS Form PTO-SB08 may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

The references were cited in the European Search Report of copending European Patent Application Number EP 03812962.3 dated August 27, 2008.

Applicants wish to bring to the Examiner's attention that we are not providing copies of US Patents or published US patent applications as instructed under 37 CFR 1.98(a)(2).

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

The Commissioner is hereby authorized to charge any required fees or credit any overpayments to Attorney Deposit Account No.: 50-4302, referencing Attorney Docket No.: BSYNEXUS-10148.

Dated: November 26, 2008

/Tyler J. Sisk/  
Tyler J. Sisk  
Registration No. 59,850  
CASIMIR JONES, S.C.  
440 Science Drive, Suite 203  
Madison, WI 53711  
608/218-6900